Oxymetazoline Uses, Dosage, Side Effects & Precautions | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Oxymetazoline
Therapeutic Class: Nasal decongestant
Subclass: Alpha-adrenergic agonist (sympathomimetic)
Specialty: ENT (Otorhinolaryngology)
Schedule (India): OTC (when used in nasal formulations ≤ 0.05%)
Route(s): Intranasal (nasal drops, spray), Ophthalmic (eye drops)
Formulations Available in India:
- Nasal spray: 0.025%, 0.05%
- Nasal drops: 0.01%, 0.025%, 0.05%
- Ophthalmic drops: 0.025%
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Nasal Congestion (Allergic rhinitis, URTI, Sinusitis)
Formulation: Nasal spray or drops (0.05%)
Adults and Adolescents ≥12 years:
- Starting dose: 1–2 sprays or 2–3 drops of 0.05% per nostril
- Titration: Not applicable
- Usual maintenance dose: 1–2 sprays or 2–3 drops per nostril twice daily
- Maximum dose: 2–3 applications per day; do not exceed 5–7 consecutive days
Clinical Notes:
- Rebound congestion (rhinitis medicamentosa) develops with use beyond 5–7 days
- Use 0.025% formulation in elderly or patients with hypertension
- Administration technique: Keep head upright for spray; tilt head back for drops
- Avoid use in patients with pre-existing nasal mucosal damage
2. Red Eye / Ocular Hyperaemia (Minor irritation or allergy)
Formulation: Ophthalmic solution 0.025%
Adults:
- Starting dose: 1–2 drops in affected eye(s)
- Titration: Not applicable
- Usual maintenance dose: 1–2 drops every 6 hours as needed
- Maximum dose: 4 applications per day; do not exceed 7 consecutive days
Clinical Notes:
- Avoid in patients with narrow-angle glaucoma
- Discontinue if redness persists beyond 72 hours or worsens
- Not for use with contact lenses in situ
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Notes |
| Epistaxis adjunct (OFF-LABEL) | 1–2 drops or sprays of 0.05% in bleeding nostril | Single use or short-term | Specialist only; used by ENT for local vasoconstriction. Evidence: Indian specialist clinical practice only |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
Nasal Congestion (URTI / Allergic rhinitis)
| Age Group | Formulation | Dose per Nostril | Frequency | Maximum Duration |
| 6 to <12 years | 0.025% drops or spray | 1–2 drops or 1 spray | Twice daily | 3–5 days |
| 2 to <6 years | 0.01% drops only | 1–2 drops | Twice daily | 3–5 days |
| <2 years | Not recommended | — | — | Use only under paediatric specialist supervision |
Safety Monitoring:
- Use lowest effective concentration
- Monitor for CNS excitation (tremors, irritability, hyperactivity) — especially in infants
- Avoid prolonged use to prevent rebound congestion
- Sprays not recommended in children <6 years due to aspiration risk
Secondary Indications — Paediatrics (Off-label, if any)
None documented in Indian sources.
RENAL ADJUSTMENT
No adjustment required (minimal systemic absorption with topical use).
HEPATIC ADJUSTMENT
| Impairment Level | Recommendation |
| Mild to Moderate | No specific adjustment; use with general caution |
| Severe | Use with caution; though systemic absorption is minimal, accumulation theoretically possible with prolonged or excessive use |
CONTRAINDICATIONS
- Hypersensitivity to oxymetazoline or any formulation excipient
- Narrow-angle glaucoma (for ophthalmic use)
- Rhinitis medicamentosa or chronic atrophic rhinitis
- Children <2 years (unless under paediatric specialist supervision)
- Concurrent use with MAO inhibitors or within 14 days of discontinuation
CAUTIONS
- Hypertension (uncontrolled or poorly controlled)
- Cardiovascular disease (ischaemic heart disease, arrhythmias)
- Diabetes mellitus
- Hyperthyroidism
- Benign prostatic hyperplasia (ophthalmic use may rarely worsen symptoms)
- Children aged 2–6 years: use only appropriate low-concentration formulations
- Prolonged or excessive use: risk of mucosal damage and rebound congestion
PREGNANCY
| Parameter | Guidance |
| Risk Category | Generally considered low-risk with short-term topical use |
| Preferred Alternatives | Saline nasal drops/irrigation preferred during pregnancy |
| When to Use | May be used for short-term relief (≤3 days) when benefits outweigh risks |
| Monitoring | Blood pressure in hypertensive mothers |
LACTATION
| Parameter | Guidance |
| Compatibility | Compatible with breastfeeding (minimal systemic absorption) |
| Preferred Alternatives | Saline irrigation or steam inhalation if possible |
| Expected Milk Levels | Negligible |
| Infant Monitoring | Observe for irritability, poor feeding (rare) |
ELDERLY
- Recommended starting formulation: 0.025% (lower concentration)
- Slower titration: Not applicable
- Extra risks: Higher susceptibility to systemic effects — hypertension, cardiac arrhythmias, glaucoma exacerbation
- Duration: Strictly limit to <5 days
- Counsel: Avoid concurrent use of other sympathomimetics
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Risk |
| MAO inhibitors (tranylcypromine, isocarboxazid, selegiline high-dose) |
Contraindicated — risk of severe hypertensive crisis
|
| Tricyclic antidepressants (amitriptyline, imipramine) | Enhanced vasoconstrictor effect; potential hypertensive response |
| Ergot alkaloids (ergotamine, dihydroergotamine) | Additive vasoconstriction; risk of peripheral ischaemia |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Risk |
| Beta-blockers | May potentiate blood pressure elevation |
| Antihypertensives | May reduce efficacy of antihypertensive therapy |
| CNS stimulants (methylphenidate, modafinil) | Additive sympathomimetic effects |
| Hydrocarbon inhalational anaesthetics (halothane) | Potential for cardiac arrhythmias with adrenergic agents |
COMMON ADVERSE EFFECTS
- Nasal dryness or stinging
- Sneezing upon application
- Transient burning sensation (ophthalmic use)
- Headache
- Insomnia (with excessive or frequent use)
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Notes |
| Rhinitis medicamentosa | Common with use >5 days; requires drug cessation |
| Tachycardia / Palpitations | If significant systemic absorption occurs |
| Hypertensive episodes | In susceptible individuals (elderly, pre-existing HTN) |
| CNS stimulation in children | Tremors, irritability, seizures (especially in overdose) |
| Angle-closure glaucoma | With ophthalmic use in predisposed individuals |
MONITORING REQUIREMENTS
| Phase | Parameters |
| Baseline | Not routinely required; consider BP monitoring in hypertensive patients |
| After initiation | Watch for rebound congestion if use extends beyond 3–5 days |
| Long-term | Avoid continued use >5 days; assess for mucosal ischaemia or atrophy |
BRANDS AVAILABLE IN INDIA
- Nasivion® (0.01%, 0.025%, 0.05% — nasal drops/spray)
- Otrivin® (0.05% — nasal spray)
- Dristan®
- Relinase®
- Visine Advanced® (ophthalmic)
PRICE RANGE (INR)
| Formulation | Approximate Cost |
| Nasal drops/spray (10 mL) | ₹25–₹80 (varies by brand and strength) |
| Ophthalmic drops (10 mL) | ₹30–₹60 |
- Not listed under NLEM price control
- Prices reflect private pharmacy retail rates
CLINICAL PEARLS
- Strictly limit duration to 3–5 days to prevent rhinitis medicamentosa; counsel patients at dispensing
- Clearly differentiate paediatric formulations (0.01–0.025%) from adult (0.05%) to avoid dosing errors
- Do not use in children <2 years without paediatric specialist input
- Educate on proper technique: upright position for spray, tilted back for drops; wait 3–5 minutes before second application
- Consider non-pharmacological measures first (saline irrigation, steam inhalation) for mild congestion
- Avoid in poorly controlled hypertension or active cardiovascular disease
TAGS
oxymetazoline; nasal decongestant; alpha agonist; rhinitis; sinusitis; URTI; paediatric caution; hypertension caution; ocular redness; OTC India; rhinitis medicamentosa
VERSION
RxIndia v0.2 — 18 Feb 2026
REFERENCES
- CDSCO approved drug list
- Indian Pharmacopoeia
- AIIMS Drug Formulary
- IAP Guidelines for Paediatric Medicine
- API Textbook of Medicine
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
- Indian ENT specialist prescribing practice
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.